Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al
The anti-obesity drug semaglutide may lower the risk of death from COVID-19, cardiovascular disease, and all causes, according to a randomized controlled trial published late last week in the Journal of the American College of Cardiology ( JACC )
demonstrated that HR-HPV18 E2 amplifies the production of ROS and causes a diminish in cellular glutathione (GSH) levels
B6 helps keep your metabolism active and supports mood and energywithout needing to eat more
The REWIND trial with dulaglutide included many patients without established ASCVD and demonstrated a consistent reduction in MACE, supporting a role in primary prevention, although the effect size was modest